Table 1.
Detection of tumor-specific mutations in cyst fluid. The fraction of samples detected and the median fraction of mutant alleles are indicated, grouped by cyst type, cancer stage, and the need for surgery.
| Fraction of samples detected (95% confidence interval) | Median fraction of mutant alleles (IQR) | Total # of samples | |
|---|---|---|---|
| Type | |||
| Non-neoplastic | 0% (0–46%) | 0% (0–0%) | 6 |
| Benign tumor | 0% (0–26%) | 0% (0–0%) | 12 |
| Borderline tumor | 83% (61–95%) | 2.4% (1.5–10.8%) | 23 |
| Type I cancer | 77% (46–95%) | 7.8% (3.3–28.7%) | 13 |
| Type II cancer | 100% (81–100%) | 60.3% (31.3–70.8%) | 18 |
| Cancer stage | |||
| Early (I and II) | 82% (48–97%) | 7.4% (3.0–30.9%) | 11 |
| Late (III and IV) | 95% (75–100%) | 51.2% (30.2–69.5%) | 20 |
| Cysts requiring surgery | |||
| No | 0% (0–26%) | 0% (0–0%) | 18 |
| Yes | 87% (75–95%) | 12.6% (2.7–40.2%) | 54 |